-
1.发明授权Methods for generating and screening fusion protein libraries and uses thereof 有权用于产生和筛选融合蛋白文库的方法及其用途公开(公告)号：US09109223B2
公开(公告)日：2015-08-18
申请号：US12097419
申请日：2006-12-22
申请人： Adrian Schwartz Mittelman , Jeannick Cizeau , Nicholas Ronald Glover , Glen Christopher MacDonald
发明人： Adrian Schwartz Mittelman , Jeannick Cizeau , Nicholas Ronald Glover , Glen Christopher MacDonald
CPC分类号： C12N15/1034 , C07K16/30 , C07K2317/21 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/92 , C07K2319/00 , C07K2319/55 , C12N15/1086 , C12P21/02 , C40B30/04 , G01N33/5014
摘要： The invention provides methods for generating fusion protein libraries, such as immunotoxin libraries. The invention also relates to libraries of recombinant cells encoding nucleic acid sequences comprising fusion proteins. In addition, the invention relates to the libraries themselves and the use of the libraries to screen for fusion proteins that are specific for target cells, such as cancer cells. Further, the invention relates to methods of improving fusion proteins and to the improved fusion proteins.
摘要翻译： 本发明提供了产生融合蛋白文库的方法，例如免疫毒素文库。 本发明还涉及编码包含融合蛋白的核酸序列的重组细胞的文库。 此外，本发明涉及文库本身以及文库用于筛选特异于靶细胞例如癌细胞的融合蛋白的用途。 此外，本发明涉及改善融合蛋白和改进的融合蛋白的方法。
-
公开(公告)号：US20130217865A1
公开(公告)日：2013-08-22
申请号：US13743672
申请日：2013-01-17
申请人： Nicholas Ronald Glover , Glen Christopher MacDonald , Joycelyn Entwistle , Jeannick Cizeau , Denis Bosc , Francina C. Chahal
发明人： Nicholas Ronald Glover , Glen Christopher MacDonald , Joycelyn Entwistle , Jeannick Cizeau , Denis Bosc , Francina C. Chahal
IPC分类号： C07K16/30 , C07K14/415 , C12N9/10
CPC分类号： C07K16/2884 , A61K38/00 , A61K39/39558 , A61K45/06 , A61K47/6819 , A61K47/6829 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K2039/505 , C07K14/415 , C07K16/30 , C07K16/3015 , C07K2317/31 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/624 , C07K2317/626 , C07K2317/77 , C07K2319/55 , C12N9/1077 , G01N33/574 , G01N2333/471 , G01N2333/70585
摘要： The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a tumor specific antibody. In addition, the invention provides tumor-specific antibodies and immunoconjugates comprising the tumor-specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the tumor-specific antibodies of the invention.
摘要翻译： 本发明提供了肿瘤特异性抗体的重链和轻链互补决定区的氨基酸和核酸序列。 此外，本发明提供包含附着于毒素或标记物的肿瘤特异性抗体的肿瘤特异性抗体和免疫缀合物及其方法和用途。 本发明还涉及使用本发明的肿瘤特异性抗体的诊断方法和试剂盒。
-
公开(公告)号：US08318472B2
公开(公告)日：2012-11-27
申请号：US12679963
申请日：2008-09-26
申请人： Jeannick Cizeau , Glen MacDonald , Arjune Premsukh
发明人： Jeannick Cizeau , Glen MacDonald , Arjune Premsukh
CPC分类号： C07K16/30 , C07K14/21 , C07K2317/622 , C07K2319/55
摘要： An optimized nucleic acid sequence encoding the immunoconjugate VB4-845 is disclosed. Modifications to the original VB4-845 nucleic acid sequence include optimization of the sequences encoding the VH region, VL region, linkers and pseudomonas exotoxin A. The modifications improved the yield of VB4-845 in an Escherichia coli expression system.
摘要翻译： 公开了编码免疫缀合物VB4-845的优化的核酸序列。 对原始VB4-845核酸序列的修饰包括优化编码VH区，VL区，接头和假单胞菌外毒素A的序列。修饰提高了大肠杆菌表达系统中VB4-845的产量。
-
4.发明授权公开(公告)号：US07750136B2
公开(公告)日：2010-07-06
申请号：US11971660
申请日：2008-01-09
申请人： Matthew Baker , Francis J. Carr , Koen Hellendoorn , Jeannick Cizeau , Glen Christopher MacDonald , Joycelyn Entwistle , Denis Georges Bosc , Nicholas Ronald Glover
发明人： Matthew Baker , Francis J. Carr , Koen Hellendoorn , Jeannick Cizeau , Glen Christopher MacDonald , Joycelyn Entwistle , Denis Georges Bosc , Nicholas Ronald Glover
IPC分类号： C07H21/04
CPC分类号： C07K16/30 , A61K38/00 , A61K47/6825 , A61K2039/505 , C07K14/415 , C07K2317/34 , C07K2317/55 , C07K2317/622 , C07K2319/00 , C07K2319/30 , C07K2319/33 , C07K2319/55
摘要： The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.
摘要翻译： 本发明提供具有生物活性的bouganin蛋白质的修饰形式，与非修饰的bouganin蛋白质相比，活化人类T细胞的倾向降低。 本发明还提供了与非修饰的T细胞表位肽相比，bouganin的T细胞表位肽和bouganin的修饰的T细胞表位肽，其具有降低的活化人T细胞的倾向。 本发明还提供了具有与附着于改良的bouganin蛋白的癌细胞结合的配体的细胞毒素。 还提供了使用本发明的细胞毒素和用于治疗人类癌症的药物组合物来抑制或破坏哺乳动物癌细胞的方法。
-
5.发明申请公开(公告)号：US20080219994A1
公开(公告)日：2008-09-11
申请号：US11971660
申请日：2008-01-09
申请人： Matthew Baker , Francis J. Carr , Koen Hellendoorn , Jeannick Cizeau , Glen Christopher MacDonald , Joycelyn Entwistle , Denis Georges Bosc , Nicholas Ronald Glover
发明人： Matthew Baker , Francis J. Carr , Koen Hellendoorn , Jeannick Cizeau , Glen Christopher MacDonald , Joycelyn Entwistle , Denis Georges Bosc , Nicholas Ronald Glover
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： C07K16/30 , A61K38/00 , A61K47/6825 , A61K2039/505 , C07K14/415 , C07K2317/34 , C07K2317/55 , C07K2317/622 , C07K2319/00 , C07K2319/30 , C07K2319/33 , C07K2319/55
摘要： The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.
摘要翻译： 本发明提供具有生物活性的bouganin蛋白质的修饰形式，与非修饰的bouganin蛋白质相比，活化人类T细胞的倾向降低。 本发明还提供了与非修饰的T细胞表位肽相比，bouganin的T细胞表位肽和bouganin的修饰的T细胞表位肽，其具有降低的活化人T细胞的倾向。 本发明还提供了具有与附着于改良的bouganin蛋白的癌细胞结合的配体的细胞毒素。 还提供了使用本发明的细胞毒素和用于治疗人类癌症的药物组合物来抑制或破坏哺乳动物癌细胞的方法。
-
公开(公告)号：US08697075B2
公开(公告)日：2014-04-15
申请号：US13297783
申请日：2011-11-16
申请人： Nicholas Ronald Glover , Glen Christopher MacDonald , Joycelyn Entwistle , Jeannick Cizeau , Francina C. Chahal
发明人： Nicholas Ronald Glover , Glen Christopher MacDonald , Joycelyn Entwistle , Jeannick Cizeau , Francina C. Chahal
IPC分类号： A61K39/00 , A61K39/395 , C07K16/30
CPC分类号： A61K39/0011 , C07K16/30 , C07K16/303 , C07K16/3046 , C07K16/3053 , C07K16/3069 , C07K2317/21 , C07K2317/41 , C07K2317/51 , C07K2317/55 , C07K2317/565 , C07K2317/92 , G01N33/57488 , G01N2500/10
摘要： The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the invention provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the cancer specific antibodies of the invention. Further, the invention provides a novel cancer-associated antigen and its uses thereof.
摘要翻译： 本发明提供癌特异性抗体的重链和轻链互补决定区的氨基酸和核酸序列。 此外，本发明提供癌症特异性抗体和包含附着于毒素或标记物的癌症特异性抗体的免疫缀合物及其方法和用途。 本发明还涉及使用本发明的癌症特异性抗体的诊断方法和试剂盒。 此外，本发明提供了一种新的癌症相关抗原及其用途。
-
公开(公告)号：US20120058106A1
公开(公告)日：2012-03-08
申请号：US13094118
申请日：2011-04-26
IPC分类号： A61K39/395 , C07H21/00 , C12N15/63 , A61P35/00 , G01N33/574 , C12Q1/68 , A61K38/00 , A61K31/7088 , C07K14/435 , C12N5/10
CPC分类号： A61K39/0011 , A61K38/00 , A61K39/00 , A61K45/06 , A61K2039/5158 , C07K14/4748 , C07K14/705 , C07K16/30 , C07K2317/24 , C07K2317/30 , C12Q1/6886 , C12Q2600/136 , G01N33/5011 , G01N33/57492 , G01N33/6893
摘要： The present invention provides a novel cancer-associated antigen that can be used in the treatment and diagnosis of cancer. Further, the invention provides amino acid and nucleic acid sequence of the novel antigen, binding proteins, and immunoconjugates. The invention also relates to diagnostic and therapeutic methods and kits.
摘要翻译： 本发明提供可用于治疗和诊断癌症的新的癌症相关抗原。 此外，本发明提供了新型抗原，结合蛋白和免疫缀合物的氨基酸和核酸序列。 本发明还涉及诊断和治疗方法和试剂盒。
-
8.发明申请Antibodies Against a Cancer-Associated Epitope of Variant NFKBIB and Uses Thereof 有权抗癌相关表位NFκBB的抗体及其用途公开(公告)号：US20100322919A1
公开(公告)日：2010-12-23
申请号：US12744523
申请日：2008-11-27
IPC分类号： A61K39/395 , C07K16/00 , C07H21/04 , G01N33/574 , C12N15/63 , C12N5/10 , C07K14/435
CPC分类号： C07K16/30 , A61K47/6825 , A61K47/6843 , A61K47/6851 , A61K2039/505 , C07K14/21 , C07K16/18 , C07K2317/21 , C07K2317/56 , C07K2317/77 , G01N33/5023 , G01N33/57496
摘要： The present application provides the amino acid and nucleic acid sequences of heavy and light chain complementarity determining regions of a cancer specific antibody directed to an epitope of variant Nuclear Factor Kappa-B inhibitor beta (NFKBIB). In addition, the application provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or a label, and methods of uses thereof. The application also relates to diagnostic methods and kits using the cancer specific antibodies herein. Further, the application provides novel cancer-associated epitopes and antigens of variant NFKBIB, and uses thereof.
摘要翻译： 本申请提供了针对变体核因子κB抑制剂β（NFκBB）的表位的癌症特异性抗体的重链和轻链互补决定区的氨基酸和核酸序列。 此外，本申请提供癌症特异性抗体和包含附着于毒素或标签的癌症特异性抗体的免疫缀合物及其使用方法。 本申请还涉及使用本文中的癌症特异性抗体的诊断方法和试剂盒。 此外，本申请提供新的癌症相关表位和变体NFκBBIB的抗原及其用途。
-
公开(公告)号：US20100254982A1
公开(公告)日：2010-10-07
申请号：US11722420
申请日：2005-12-21
申请人： Nicholas Ronald Glover , Glen Christopher MacDonald , Joycelyn Entwistle , Jeannick Cizeau , Francina C. Chahal
发明人： Nicholas Ronald Glover , Glen Christopher MacDonald , Joycelyn Entwistle , Jeannick Cizeau , Francina C. Chahal
IPC分类号： A61K39/395 , C07K14/00 , C07H21/00 , C12N15/74 , C12N1/21 , C07K16/18 , C07K16/28 , G01N33/574 , A61K38/16 , A61K31/7088 , A61K39/00 , C12Q1/68 , A61P35/00
CPC分类号： A61K39/0011 , C07K16/30 , C07K16/303 , C07K16/3046 , C07K16/3053 , C07K16/3069 , C07K2317/21 , C07K2317/41 , C07K2317/51 , C07K2317/55 , C07K2317/565 , C07K2317/92 , G01N33/57488 , G01N2500/10
摘要： The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the invention provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the cancer specific antibodies of the invention. Further, the invention provides a novel cancer-associated antigen and its uses thereof.
摘要翻译： 本发明提供癌特异性抗体的重链和轻链互补决定区的氨基酸和核酸序列。 此外，本发明提供癌症特异性抗体和包含附着于毒素或标记物的癌症特异性抗体的免疫缀合物及其方法和用途。 本发明还涉及使用本发明的癌症特异性抗体的诊断方法和试剂盒。 此外，本发明提供了一种新的癌症相关抗原及其用途。
-
10.发明申请公开(公告)号：US20050238642A1
公开(公告)日：2005-10-27
申请号：US11084080
申请日：2005-03-18
申请人： Matthew Baker , Francis Carr , Koen Hellendoorn , Jeannick Cizeau , Glen MacDonald , Joycelyn Entwistle , Denis Bosc , Nicholas Glover
发明人： Matthew Baker , Francis Carr , Koen Hellendoorn , Jeannick Cizeau , Glen MacDonald , Joycelyn Entwistle , Denis Bosc , Nicholas Glover
IPC分类号： A61K38/00 , A61K38/16 , A61K39/395 , A61K47/48 , A61P35/00 , C07K7/08 , C07K14/415 , C07K16/30 , C07K16/44 , C07K19/00 , C12N15/11 , C12N15/13 , C12N15/29 , C12N15/62
CPC分类号： C07K16/30 , A61K38/00 , A61K47/6825 , A61K2039/505 , C07K14/415 , C07K2317/34 , C07K2317/55 , C07K2317/622 , C07K2319/00 , C07K2319/30 , C07K2319/33 , C07K2319/55
摘要： The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.
摘要翻译： 本发明提供具有生物活性的bouganin蛋白质的修饰形式，与非修饰的bouganin蛋白质相比，活化人类T细胞的倾向降低。 本发明还提供了与非修饰的T细胞表位肽相比，bouganin的T细胞表位肽和bouganin的修饰的T细胞表位肽，其具有降低的活化人T细胞的倾向。 本发明还提供了具有与附着于改良的bouganin蛋白的癌细胞结合的配体的细胞毒素。 还提供了使用本发明的细胞毒素和用于治疗人类癌症的药物组合物来抑制或破坏哺乳动物癌细胞的方法。
-
-
-
-
-
-
-
-
-
搜索结果
30 条记录 (耗时 0.032 秒)
